OTCMKTS:ISCO International Stem Cell Q2 2025 Earnings Report $0.33 +0.01 (+1.54%) As of 01:20 PM Eastern ProfileEarnings History International Stem Cell EPS ResultsActual EPS$0.01Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AInternational Stem Cell Revenue ResultsActual Revenue$2.45 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AInternational Stem Cell Announcement DetailsQuarterQ2 2025Date8/14/2025TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile International Stem Cell Earnings HeadlinesISCO - International Stem Cell CorporationSeptember 18, 2026 | seekingalpha.comInternational Stem Cell (OTCMKTS:ISCO) Stock Price Passes Above 200-Day Moving Average - Here's WhySeptember 18, 2026 | americanbankingnews.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 29 at 1:00 AM | Stansberry Research (Ad)Der aktuelle Kurs der International Stem Cell Corp Aktie beträgt 0,490.August 27, 2026 | de.investing.comما هو سعر سهم International Stem Cell (ISCO) اليوم؟August 22, 2026 | sa.investing.comSpaceflight accelerates the aging of human blood-forming stem cellsSeptember 9, 2025 | yahoo.comSee More International Stem Cell Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like International Stem Cell? Sign up for Earnings360's daily newsletter to receive timely earnings updates on International Stem Cell and other key companies, straight to your email. Email Address About International Stem CellInternational Stem Cell (OTCMKTS:ISCO) Corporation is a biotechnology company focused on developing human stem cell-based products and therapies. Its research has centered on proprietary parthenogenetic human stem cells, which are derived from unfertilized human oocytes and are intended to provide a potentially useful source of cells for regenerative medicine. The company has pursued applications in tissue engineering and cell therapy, including programs involving corneal tissue and other specialized cell types. Its development activities have included research into producing differentiated cells from parthenogenetic stem cells for potential use in treating disease and repairing damaged tissue. International Stem Cell has also operated through subsidiaries and related businesses involved in commercial skincare products. Its Lifeline Skin Care business markets products incorporating human stem cell-derived ingredients, extending the company’s activities beyond therapeutic research into the consumer skincare market.View International Stem Cell ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles CarMax Just Gave Investors a Better Reason to Believe in the TurnaroundBernstein Downgrades 3 Cybersecurity Stocks: How Concerned Should Investors Be?Brewing Trouble? Starbucks Spills the Beans on 250 Store ClosuresMarketBeat Week in Review – 09/21 - 09/25Analyst Rating Boosts May Signal More Upside for These 3 Stocks3 Stocks Under the Microscope After Large Insider Sales3 Healthcare Stocks Showing Why the Sector Still Has Momentum Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
